What is Lurbinectedin?
Lurbinectedin (brand name Zepzelca) is an intravenous alkylating agent that inhibits tumor growth by trapping topoisomerase I complexes in DNA, leading to DNA breaks and cell death. The FDA approved it in June 2020 for adults with metastatic small cell lung cancer (SCLC) that progressed after platinum-based chemotherapy.[1]
How Does Lurbinectedin Work?
It binds the minor groove of DNA, alkylates nucleotides, and blocks RNA polymerase II elongation, causing double-strand breaks during transcription. This selectivity targets cancer cells with high transcription rates, sparing normal cells more effectively than traditional alkylators.[1]
Who Makes Lurbinectedin and Approval Status?
Jazz Pharmaceuticals, in partnership with Pharma Mar, developed and markets Zepzelca. Approval came via accelerated pathway based on the phase 2 ATLANTIS trial basket study, showing 35% overall response rate and 5.3-month median duration in SCLC patients.[1] Full approval requires confirmatory trials.
When Does Lurbinectedin Patent Expire?
Core U.S. composition-of-matter patents for lurbinectedin expire between 2028 and 2033, with key Patent No. 8,410,066 (covering the compound) listed until December 2028. Method-of-use patents extend protection to 2035 in some cases. DrugPatentWatch tracks 14 Orange Book patents; check litigation updates as challenges from generics like Viatris are ongoing.[2]
What Are Common Dosing and Side Effects?
Administered as 3.2 mg/m2 IV over 60 minutes on day 1 of a 21-day cycle, with premedication for nausea. Common side effects include fatigue (60%), nausea (55%), decreased appetite (45%), and myelosuppression (neutropenia 53%, anemia 45%). Severe risks: pneumonia, hepatotoxicity; monitor blood counts.[1]
How Does It Compare to Topotecan in SCLC?
Lurbinectedin showed better tolerability and response rates than topotecan (standard second-line SCLC therapy) in head-to-head trials: 35.2% ORR vs. 25.2%, with longer progression-free survival (5.1 vs. 3.9 months). FDA preferred it over topotecan for relapsed SCLC.[1]
Ongoing Trials and Future Uses?
Phase 3 trials test combinations like lurbinectedin + atezolizumab (IMforte, NCT04863035) for extensive-stage SCLC frontline, and with irinotecan for other solid tumors. Early data in pleural mesothelioma and ovarian cancer suggest expansion potential.[1]
Pricing and Access?
A single Zepzelca cycle costs about $13,000-$15,000 (U.S. wholesale), or $180,000+ annually. Patient assistance programs from Jazz cover copays for eligible uninsured/underinsured.[3]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf
[2] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/ZEPZELCA
[3] Jazz Pharmaceuticals Pricing: https://www.zepzelca.com/hcp/support-and-resources